BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Human Pheromone Sciences (EROX) Announces Fourth Quarter and Full Year Results


3/31/2011 7:57:23 AM

SAN JOSE, Calif., March 30, 2011 /PRNewswire/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the three months and the year ended December 31, 2010. For the three months ended December 31, 2010, net revenue was $225,000, representing a 1% increase from revenues of $223,000 in the prior year period, and resulted in net income of $118,000 ($0.03 per share) as compared with net loss of $29,000 ($0.01 per share) for the three months ended December 31, 2009, a $247,000 improvement. For the year ending December 31, 2010, net revenues of $806,000, were 9% less than revenues of $885,000 generated in the year ended December 31, 2009. The net loss in the current year of $97,000 ($0.02 per share) was a $187,000, or 66%, reduction from the $284,000 loss ($0.07 per share) recorded for the year ended December 31, 2009.

Administrative expenses reductions of approximately $92,000 gave rise in net income of $118,000 during the three months ending December 31, 2010 as compared with a net loss of $29,000 in the prior year period. The administrative expense reductions for the year ended December 31, 2010 were $141,000, or 16% as the Company reduced operating costs to the current levels of revenues.

The Company is sorely aware that it needs additional agreements with current licensees, expansion of the business with new licensees and new relationships outside of the way the Company currently conducts its business. "We continue to work in all three of these areas on a daily basis," a spokesperson indicated. The Company further noted that it continues to seek alternative distribution channels for its technologies and to generate marketing interest in its patent-pending sea coral based compound, classified as ER 303.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

Tables follow

HUMAN PHEROMONE SCIENCES, INC.




Condensed Balance Sheets




(Dollars in thousands)





December 31,

December 31,


2010

2009




Assets






Cash and cash equivalents

$ 92

$ 350

Accounts receivable

108

141

Inventories

26

58

Other current assets

49

40

Property and equipment, net

-

1




Total

$ 275

$ 590







Liabilities and Shareholders' Equity






Accounts payable

$ 42

$ 60

Other current liabilities

102

135

Deferred income - current

146

194

Deferred income non-current

24

158

Common stock

21,098

21,083

Accumulated deficit

(21,137)

(21,040)




Total

$ 275

$ 590



HUMAN PHEROMONE SCIENCES, INC.

Condensed Statements of Operations






(Dollars in thousands, except per-share data)












Three months

Year


ended December 31,

ended December 31,


2010

2009

2010

2009






Net revenues

$225

$223

$806

$885






Cost of goods sold

21

28

128

195

Research and development

(17)

30

23

85

Selling, general and administrative

103

195

750

891






Income (loss) from operations

118

(30)

(95)

(286)






Other income

-

1

-

3






Income (loss) before provision for





income taxes

118

(29)

(95)

(283)






Provision for Income taxes

-

-

2

1






Net income (loss)

$118

$(29)

$(97)

$(284)
















Net income (loss) per share





Basic

$0.03

$(0.01)

$(0.02)

$(0.07)

Fully diluted

$0.02

$(0.01)

$(0.02)

$(0.07)











Weighted average number of shares -





Basic

4,152

4,152

4,152

4,152

Fully diluted

4,992

4,152

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->